127980-30-7

Upstream product

• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 1878-67-7 3-Bromophenylacetic acid 

Downstream Products

• 1027988-54-0 [3-((1S,2R,3R,4R)-3-Hydroxymethyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-acetic acid 
• 127980-34-1 <1S-1α,2α,3α,4α>-3-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzeneacetic acid, methyl ester 
• 127980-35-2 [3-((1S,2R,3R,4R)-3-Acetoxymethyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-acetic acid 
• 127980-32-9 [(1R,2R,3R,4S)-3-(3-{2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol 
• 127980-33-0 Acetic acid (1R,2R,3R,4S)-3-(3-{2-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl ester 
• 127980-20-5 C₂₄H₂₇N₃O₄ 
• 135613-43-3 Acetic acid (1R,2R,3R,4S)-3-[2-acetoxy-2-(3-{2-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-phenyl)-ethyl]-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl ester 
• 128051-34-3 <1S-1α,2α,3α,4α>-3-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzeneacetic acid 
• 127980-36-3 {3-[1-Acetoxy-2-((1S,2R,3R,4R)-3-acetoxymethyl-7-oxa-bicyclo[2.2.1]hept-2-yl)-ethyl]-phenyl}-acetic acid methyl ester 
• 1027489-82-2 {3-[1-Acetoxy-2-((1S,2R,3R,4R)-3-acetoxymethyl-7-oxa-bicyclo[2.2.1]hept-2-yl)-ethyl]-phenyl}-acetic acid 
• 128051-36-5 [3-((1S,2R,3S,4R)-3-Formyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-acetic acid methyl ester 
• 127980-22-7 1-(3-{2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-phenyl)-2-((1S,2R,3R,4R)-3-hydroxymethyl-7-oxa-bicyclo[2.2.1]hept-2-yl)-ethanol 
• 127980-31-8 (3-{2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-phenyl)-((1S,2S,3R,4R)-3-hydroxymethyl-7-oxa-bicyclo[2.2.1]hept-2-yl)-methanol 

Relevant academic research and scientific papers

Prostaglandin analogs

Thromboxane receptor antagonist activity is exhibited by compounds of the formula STR1 wherein: V is --(CH 2) m --, --O--, or STR2 but if V is --O--or STR3 R 3 and R 4 must complete an aromatic ring; W is --(CH 2) 2 --, --CH CH-- or phenylene;X is a single bond, --CH CH--, --(CH 2) n --, or --O--(CH 2) n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long;Y is --CO 2 H, --CO 2 alkyl, --CO 2 alkali metal, --CH 2 OH, --CONHSO 2 R 5, --CONHR 6, or --CH 2 -5-tetrazolyl;Z is O or NH;R 3 and R 4 are each independently hydrogen or alkyl or R 3 and R 4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.

Interphenylene 7-oxabicyclo[2.2.1]heptane thromboxane A2 antagonists. Semicarbazone ω-chains

A series of chiral interphenylene 7-oxabicyclo[2.2.1]heptane semicarbazones 19-26 were prepared and evaluated for their in vitro thromboxane (TxA2) antagonistic activity and in vivo duration of action. The potency of 19-26 was found to be highly dependent on the substitution pattern of the interphenylene ring and decreased in the order ortho > meta >> para. SQ 35,091 (25), [1S-(1α,2α,3α,4α)]-2-[[3-[[[(phenylamino)carbonyl]hydrazono] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, was identified as a potent and long-acting TxA2 antagonist. In human platelet rich plasma SQ 35,091 inhibited arachidonic acid (800 μM) and U-46,619 (10 μM) induced aggregation with I50 values of 3 and 12 nM, respectively. In contrast, no inhibition of ADP (20 μM) induced aggregation was observed at >1000 μM. Receptor binding studies with [3H]-SQ 29,548 showed SQ 35,091 was a competitive antagonist with a K(d) value of 1.0 ± 0.1 nM in human platelet membranes. In vivo SQ 35,091 (0.2 mg/kg po) showed extended protection (T50 = 16 h) from U-46,619 (2 mg/kg iv) induced death in mice. These compounds have for the first time demonstrated that a metabolically stable interphenylene α-sidechain can be introduced into a prostanoid-like series of TxA2 antagonists with the maintenance of potent antagonistic activity.